©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 27, 2025; 17(11): 110946
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.110946
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.110946
Autoimmune-like hepatitis induced by drugs: Still many unanswered questions
Fernando Bessone, Department of Gastroenterology and Hepatology, Facultad de Ciencias Médicas, Hospital Provincial del Centenario, University of Rosario School of Medicine, Rosario 2000, Santa Fe, Argentina
Einar S Bjornsson, Landspitali University Hospital, Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland
Author contributions: Bessone F and Bjornsson ES designed the topics to be covered, reconstructed the manuscript, made revisions, wrote small comments and organized the references; and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Fernando Bessone, Professor, Department of Gastroenterology and Hepatology, Facultad de Ciencias Médicas, Hospital Provincial del Centenario, University of Rosario School of Medicine, Urquiza 3101, Rosario 2000, Santa Fe, Argentina.
Received: June 19, 2025
Revised: July 6, 2025
Accepted: October 23, 2025
Published online: November 27, 2025
Processing time: 161 Days and 18.4 Hours
Revised: July 6, 2025
Accepted: October 23, 2025
Published online: November 27, 2025
Processing time: 161 Days and 18.4 Hours
Core Tip
Core Tip: Drug-induced autoimmune-like hepatitis is a challenging issue in clinical practice. Although some parts of the puzzle have been put in place, there are still several events to be solved. These include the lack of a clear classification of the disease, the role of liver pathology and how treatment should be approached in terms of corticosteroid dosage, for how long it should be prescribed and when to stop therapy.